While no financial figures are provided, ASCO acceptance is a material positive for clinical credibility and investor visibility. Monitor the May 21 abstract release and subsequent trial enrollment trends in IMPACT and ACAPELLA for signs of momentum. This could support future partnership or funding opportunities.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $1.02entry
- T+1 · 7mo ago 0.00%α +0.49% · $1.02
- T+5 · 7mo ago 0.00%α −0.40% · $1.02
- T+20 · 6mo ago +150.98%α +146.02% · $2.56
- T+60 · 4mo ago +223.53%α +218.75% · $3.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau Medical announced that a pooled analysis of safety and efficacy data from 58 patients across three clinical studies of its Alpha DaRT therapy for advanced pancreatic cancer has been accepted for presentation at the 2026 ASCO Annual Meeting, a premier oncology conference. This represents a significant scientific validation of its clinical program and builds momentum for its ongoing IMPACT and ACAPELLA trials in the U.S. and France.
Key Facts
- Abstract titled 'Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer' accepted for presentation at the 2026 ASCO Annual Meeting.
- Pooled data includes 58 patients from three prospective clinical studies conducted in Canada and Israel.
- ASCO is the world's largest and most prestigious oncology conference; abstract acceptance is peer-reviewed and highly competitive.
- Alpha Tau highlighted this as a major milestone, validating the maturity and strength of its pancreatic cancer clinical evidence base.
- The company's flagship IMPACT trial in the U.S. and ACAPELLA trial in France are actively advancing.
Financial Impact
No direct financial impact disclosed; potential long-term upside from clinical validation and de-risking of development path.
Risk Factors
- Pooled data is preliminary and not yet peer-reviewed in full; final results may differ.
- Alpha Tau remains pre-revenue with significant funding needs; clinical progress does not guarantee commercial success.
- Forward-looking statements dominate the release; actual outcomes depend on trial execution and regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-047783 |
| Document: ea0287690-6k_alphatau.htm | 0001213900-26-047783 |
| Document: 0001213900-26-047783-index-headers.html | 0001213900-26-047783 |
| Document: 0001213900-26-047783-index.html | 0001213900-26-047783 |
| Document: 0001213900-26-047783.txt | 0001213900-26-047783 |
Track record
14 reports on DRTSW
8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers